drugset / Trial / NCT00508209
Bortezomib and High-dose Melphalan at Myeloma Relapse
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The prognosis after retreating with high-dose melphalan with stem cell support after first relapse after high-dose treatment is dependent on the time to first relapse. Bortezomib can increase chemosensitivity of e.g. melphalan. The trial aims at determining the toxicity of adding bortezomib to high-dose melphalan with stem cell support and evaluating whether the time to a second relapse can be prolonged.
Timeline
- Start
- 2007-07
- Primary completion
- 2009-06
- Completion
- 2010-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | — |